Industry Reports
Abbott reports third-quarter 2013 results
Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an operational basis, with strong performance in Diagnostics and Medical Devices. ...
Industry Reports
Adocia announces its Q1 2013 revenues
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today its Q1 2013 revenues. Detail of the Q1 2013 revenues In thousands of euros...
Industry Reports
Bristol-Myers Squibb reports first quarter 2013 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported financial results for the first quarter of 2013, and confirmed GAAP EPS and non-GAAP EPS guidance ranges for 2013. Bristol-Myers Squibb posted first quarter 2013 net sales of $3.8 billion, a decrease...
Industry Reports
Abbott reports first-quarter 2013 results
Abbott announced financial results for the first quarter ended March 31, 2013. Worldwide sales of nearly $5.4 billion increased 3.5 percent on an operational basis, consistent with previous guidance, driven by 9.0 percent operational sales growth in Nutrition...
Industry Reports
Bristol-Myers Squibb to Announce Results for First Quarter 2013 on April 25
Bristol-Myers Squibb Company will announce results for the first quarter of 2013 on Thursday April 25 2013. During a conference call at 10:30 a.m. EDT on April 25 company executives will review financial information and will address inquiries...
Industry Reports
A strong cash position of EUR 30.5 million, an annual loss of EUR 6.0 million and significant clinical progress of Adocia projects
Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today its financial results for 2012. The financial statements were approved by the board of directors of...
Industry Reports
Adocia reports 2012 revenue multiplied by 2.5 with a strong cash position
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines with already approved therapeutic proteins, announces today its revenue for the full year and last quarter of 2012. Breakdown of the operating...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read